A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: Part II

Jose De Leon; Neil B. Sandson; Kelly L. Cozza

doi:10.1176/appi.psy.49.4.347

A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: Part II

Jose De Leon, Neil B. Sandson, Kelly L. Cozza

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Original language	English
Pages (from-to)	347-361
Number of pages	15
Journal	Psychosomatics
Volume	49
Issue number	4
DOIs	https://doi.org/10.1176/appi.psy.49.4.347
State	Published - 2008

Bibliographical note

Funding Information:
In the past year, Dr. de Leon has been on the advisory board of Roche Molecular Systems, Inc. He has received investigator-initiated grants from Roche Molecular Systems, Inc. , and Eli Lilly Research Foundation ; he has lectured supported by Eli Lilly, Janssen, and Roche Molecular Systems, Inc. Roche Molecular Systems, Inc. , markets the AmpliChip CYP450 microarray that detects CYP2D6 and CYP2C19 gene variations.

ASJC Scopus subject areas

Arts and Humanities (miscellaneous)
Applied Psychology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1176/appi.psy.49.4.347

Cite this

@article{c7cb0fdd64164487a8d56b1425234435,

title = "A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: Part II",

author = "{De Leon}, Jose and Sandson, {Neil B.} and Cozza, {Kelly L.}",

note = "Funding Information: In the past year, Dr. de Leon has been on the advisory board of Roche Molecular Systems, Inc. He has received investigator-initiated grants from Roche Molecular Systems, Inc. , and Eli Lilly Research Foundation ; he has lectured supported by Eli Lilly, Janssen, and Roche Molecular Systems, Inc. Roche Molecular Systems, Inc. , markets the AmpliChip CYP450 microarray that detects CYP2D6 and CYP2C19 gene variations. ",

year = "2008",

doi = "10.1176/appi.psy.49.4.347",

language = "English",

volume = "49",

pages = "347--361",

number = "4",

}

TY - JOUR

T1 - A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics

T2 - Part II

AU - De Leon, Jose

AU - Sandson, Neil B.

AU - Cozza, Kelly L.

N1 - Funding Information: In the past year, Dr. de Leon has been on the advisory board of Roche Molecular Systems, Inc. He has received investigator-initiated grants from Roche Molecular Systems, Inc. , and Eli Lilly Research Foundation ; he has lectured supported by Eli Lilly, Janssen, and Roche Molecular Systems, Inc. Roche Molecular Systems, Inc. , markets the AmpliChip CYP450 microarray that detects CYP2D6 and CYP2C19 gene variations.

PY - 2008

Y1 - 2008

UR - http://www.scopus.com/inward/record.url?scp=46149124547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46149124547&partnerID=8YFLogxK

U2 - 10.1176/appi.psy.49.4.347

DO - 10.1176/appi.psy.49.4.347

M3 - Article

C2 - 18621942

AN - SCOPUS:46149124547

SN - 0033-3182

VL - 49

SP - 347

EP - 361

JO - Psychosomatics

JF - Psychosomatics

IS - 4

ER -

A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: Part II

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this